Patents Assigned to DAS-MG, Inc.
  • Use and composition for treating myasthenia gravis and other myasthenic syndromes
    Patent number: 11896582
    Abstract: The present invention provides a new compositions and methods to enable the safe administration of pyridostigmine to mammalian subjects, including those with myasthenic syndromes including Myasthenia Gravis, with said compositions comprising combinations, including fixed-dose combinations, of an antagonist of the 5-hydroxytryptamine subtype-3 receptor (“5HT3-antagonist”) with an effective dose of pyridostigmine. The compositions and methods of the present invention provide for an increase in the tolerable dose of pyridostigmine over that of pyridostigmine when administered alone.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: February 13, 2024
    Assignee: DAS-MG, INC.
    Inventor: Kathleen E. Clarence-Smith
  • Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
    Patent number: 11752141
    Abstract: The present invention describes the use of a NK1-antagonist, in constant combination with pyridostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective pyridostigmine bromide daily dose without the dose-limiting gastro-intestinal adverse effects.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: September 12, 2023
    Assignee: DAS-MG, Inc.
    Inventor: Kathleen Clarence-Smith
  • Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
    Patent number: 11389420
    Abstract: The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: July 19, 2022
    Assignee: DAS-MG, Inc.
    Inventor: Kathleen Clarence-Smith
  • Use and composition for treating myasthenia gravis and other myasthenic syndromes
    Patent number: 10842778
    Abstract: The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrome, notably myasthenia gravis, by providing a therapeutically effective pyridostigmine bromide daily dose without the typical adverse effects.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: November 24, 2020
    Assignee: DAS-MG, INC.
    Inventor: Kathleen E. Clarence-Smith
  • USE AND COMPOSITION FOR TREATING MYASTHENIA GRAVIS AND OTHER MYASTHENIC SYNDROMES
    Publication number: 20200129481
    Abstract: The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrome, notably myasthenia gravis, by providing a therapeutically effective pyridostigmine bromide daily dose without the typical adverse effects.
    Type: Application
    Filed: November 27, 2019
    Publication date: April 30, 2020
    Applicant: DAS-MG, Inc.
    Inventor: Kathleen E. Clarence-Smith